The estimated Net Worth of Michael M. Jafar is at least $6.62 Milione dollars as of 25 January 2021. Mr. Jafar owns over 2,699 units of Evolus Inc stock worth over $2,669,975 and over the last 6 years he sold EOLS stock worth over $20,135. In addition, he makes $3,929,160 as Chief Commercial Officer at Evolus Inc.
Michael has made over 2 trades of the Evolus Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 2,699 units of EOLS stock worth $20,135 on 25 January 2021.
The largest trade he's ever made was buying 12,800 units of Evolus Inc stock on 14 September 2018 worth over $266,624. On average, Michael trades about 1,937 units every 108 days since 2018. As of 25 January 2021 he still owns at least 174,851 units of Evolus Inc stock.
You can see the complete history of Mr. Jafar stock trades at the bottom of the page.
Michael M. Jafar serves as Chief Commercial Officer of the Company. From April 2017 to June 2018, he served as Vice President, Medical Aesthetics at Allergan. Mr. Jafar has worked in various leadership capacities within Allergan since March 2003, including as Associate Vice President, Strategic Marketing and Communications of the Medical Aesthetics division from May 2015 to April 2017 and roles as Senior Director of Marketing for aesthetic products such as SkinMedica, Latisse and Juvederm from October 2011 to May 2015. Mr. Jafar holds an M.B.A. from the University of Southern California and a B.B.A. from the University of San Diego
As the Chief Commercial Officer of Evolus Inc, the total compensation of Michael Jafar at Evolus Inc is $3,929,160. There are no executives at Evolus Inc getting paid more.
Michael Jafar is 39, he's been the Chief Commercial Officer of Evolus Inc since 2020. There are 12 older and no younger executives at Evolus Inc. The oldest executive at Evolus Inc is Peter Farrell, 78, who is the Independent Director.
Michael's mailing address filed with the SEC is 520 Newport Center Dr #1200, Newport Beach, CA 92660, USA.
Over the last 7 years, insiders at Evolus Inc have traded over $244,915,132 worth of Evolus Inc stock and bought 3,308,677 units worth $53,545,237 . The most active insiders traders include Biopharma, Inc. Aeon, Inc. Medytox e 1 Llc Alphaeon. On average, Evolus Inc executives and independent directors trade stock every 25 days with the average trade being worth of $3,606,270. The most recent stock trade was executed by Sandra Beaver on 6 September 2024, trading 3,276 units of EOLS stock currently worth $49,074.
evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.
Evolus Inc executives and other stock owners filed with the SEC include: